Tag Archive > Metastatic Breast Cancer

DGAP-News: WILEX AG has been selected to give several presentations at ASCO

http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 / Symbol WL6. Contact Katja Arnold (CIRO) Corporate Communications WILEX AG Grillparzerstr. 10 81675 Munich, Germany Tel.: +49 (0)89-41 31 38-126 Fax: +49 (0)89-41 31 38-99 Email: www.wilex.com ISIN: DE0006614720 WKN: 661472 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart End of News DGAP […]

Continue reading

, , , , , , , , , , ,

CellSearch® ‘Liquid Biopsy’ Approved for Breast Cancer Patients in China

Raritan, New Jersey (ots/PRNewswire) – Veridex, LLC today announced approval from the China State Food & Drug Administration (SFDA) for the CellSearch(R) circulating tumor cell (CTC) test as an in vitro diagnostic for women with metastatic breast cancer. This makes CellSearch(R) the first and only approved CTC test for cancer patients in China, which is […]

Continue reading

, , , ,

AstraZeneca Begins a New Global Study of FASLODEX® (Fulvestrant) 500 mg Injection in Patients With Hormone Receptor-Positive Advanced Breast Cancer

London (ots/PRNewswire) – FALCON (Fulvestrant and AnastrozoLe COmpared in hormonal therapy Naïve advanced breast cancer) trial to compare fulvestrant to anastrozole (ARIMIDEX(R)) tablets in hormonal therapy-naïve, postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer. AstraZeneca [http://www.astrazeneca.com ] today announced the start of a Phase III registration study (FALCON), a global clinical trial […]

Continue reading

, , ,

Eisai Expands in Israeli Market With Approval of Halaven

Hatfield, England (ots/PRNewswire) – Metastatic breast cancer treatment Halaven(R) (eribulin) provides a statistically significant overall survival benefit for women with the disease Halaven(R) (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease, has recently received registration approval from the […]

Continue reading

, , , , , , , , ,

New Breast Cancer Treatment Available in France

Hatfield, England (ots/PRNewswire) – Reimbursement granted for Halaven(R) (eribulin) for women with locally advanced or metastatic breast cancer Halaven(R) (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease, has today received reimbursement approval from the French health authorities. Prior […]

Continue reading

, , , , ,

Eisai Announces Preliminary Results of Phase III Study of Halaven® (Eribulin) in Locally Advanced or Metastatic Breast Cancer

Hatfield, England (ots/PRNewswire) – Eisai Europe Limited today announces preliminary results from a recently completed Phase III study (Study 301) comparing Halaven(R) (eribulin) and Xeloda(R) (capecitabine). The study enrolled women with locally advanced or metastatic breast cancer in an earlier line of treatment than eribulin is currently licensed for. Preliminary results showed that the trial […]

Continue reading

, , , , , , , , , , ,

German Federal Regulator Confirms Additional Benefit of eribulin for Metastatic or Locally Advanced Breast Cancer

Frankfurt And Hatfield, England (ots/PRNewswire) – ? The German Federal Joint Committee (G-BA), the supreme decision-making body of the self-governing medical system in Germany, announced that it considers the use of Halaven(R) (eribulin) to have additional benefit versus comparative treatments, defined by the G-BA for women who have already had extensive prior treatment of metastatic […]

Continue reading

, , , , , , ,

G-BA bestätigt: Zusatznutzen von Eribulin beim metastasierten oder lokal fortgeschrittenen Brustkrebs

Frankfurt am Main (ots) – Der Gemeinsame Bundesausschuss (G-BA) gab heute seine Entscheidung bekannt, dass für Halaven® (Eribulin) für Frauen, die bereits umfassend gegen metastasierten oder lokal fortgeschrittenen Brustkrebs therapiert wurden, ein zusätzlicher Nutzen vorliegt. Im Gegensatz zur Einschätzung des IQWiG (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen) stellt die heutige Bewertung durch den G-BA […]

Continue reading

, , , , , , , , , ,

Eisai Opens Representative Office in Dubai

Hatfield, England (ots/PRNewswire) – New EMEA Dubai Office Part of Expansion Plans into Middle East and Parts of Africa PRESS RELEASE NOT INTENDED FOR DUBAI MEDIA Japanese company Eisai is expanding its geographical and patient reach by opening a new regional representative office in Dubai today. The Eisai EMEA (Europe, Middle East and Africa) Dubai […]

Continue reading

, , , , , , , ,

Stellungnahmeverfahren zu IQWiG-Bericht über Halaven®-Dossier eröffnet / Zusatznutzen von Eribulin beim Brustkrebs: Beurteilung des IQWiG ist für Eisai nicht nachvollziehbar

Frankfurt/Main (ots) – Mit Überraschung und Unverständnis hat das Unternehmen Eisai die Bewertung des Institutes für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) zur Kenntnis genommen, wonach dem Wirkstoff Eribulin, der als einziges Monotherapeutikum in der Therapie stark vorbehandelter Frauen mit metastasiertem oder lokal fortgeschrittenem Mammakarzinom* einen Überlebensvorteil gezeigt hat, angeblich kein dokumentierter Zusatznutzen zukommt. Die […]

Continue reading

, , , , , , , , , , ,

In einer im lancet veröffentlichten studie zeigt Halaven(TM) (Eribulin) von Eisai eine signifikante verbesserung des gesamtüberlebens im vergleich zu derzeitigen therapien für stark vorebehandelten metastasierten brustkrebs

Hatfield, England (ots/PRNewswire) – In der Fachzeitschrift Lancet wurden heute neue Studiendaten veröffentlicht, die dazu beitragen könnten, Halaven(TM) (Eribulin) von Eisai als möglichen neuen Behandlungsstandard für Frauen mit stark vorbehandeltem metastasiertem Brustkrebs (MBC – Metastatic Breast Cancer) zu etablieren. In der EMBRACE-Studie (von Eisai durchgeführte Studie zur Bewertung der Behandlung nach Wahl des Arztes bei […]

Continue reading

, , , , , , , , , , , , , , ,

Eisais Eribulin-Mesylat hält den globalen Überlebensvorteil bei Patientinnen mit metastasierendem Brustkrebs aufrecht – ungeachtet des Tumor-Hormonrezeptorstatus

Mailand (ots/PRNewswire) – Weitere Ergebnisse der heute auf dem Kongress der Europäischen Gesellschaft für klinische Onkologie (European Society of Medical Oncology, ESMO) Kongress vorgestellten EMBRACE Phase III-Studie haben gezeigt, dass Eisais Eribulin Mesylate den Vorteil der Gesamtüberlebensdauer (OS) im Vergleich zu einer Therapie nach Wahl ihres behandelnden Arztes (TPC/Treatment of Phycisians’s Choice) bei Patientinnen mit […]

Continue reading

, , , , , , , , , , , ,

Global Phase III Study Results Show Eribulin Meets Primary Endpoint Of Overall Survival

London (ots/PRNewswire) – – Eisai Plans to Submit Marketing Authorization Applications for. Eribulin Mesylate in Locally Advanced or Metastatic Breast Cancer Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) today announced preliminary results from a recently completed Phase III study with E7389 (generic name: eribulin mesylate, “eribulin”), discovered and developed by the Company, […]

Continue reading

, , , , , , , , ,

European Regulator Gives Positive Opinion for the use of Avastin in Combination With docetaxel for the First-Line Treatment of Advanced Breast Cancer

Basel (ots/PRNewswire) – – For non-US, non-UK and non-Austrian Media Patients with advanced (metastatic) breast cancer will be able to benefit from treatment with Avastin (bevacizumab) as a result of a new broader label recommendation in Europe, Roche announced today. The positive opinion issued by the European Committee for Medicinal Products for Human Use (CHMP) […]

Continue reading

, , , , , , , , , , , ,

Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival

Paris and Brisbane, California (ots/PRNewswire) – – Data Highlighted in Plenary Session of 2009 American Society of Clinical Oncology Annual Meeting Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 clinical trial of BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor, in combination with […]

Continue reading

, , , , , , ,

prev posts